|
1
|
Skálová A, Vanecek T, Sima R, Laco J,
Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH,
Passador-Santos F, et al: Mammary analogue secretory carcinoma of
salivary glands, containing the ETV6-NTRK3 fusion gene: A hitherto
undescribed salivary gland tumor entity. Am J Surg Pathol.
34:599–608. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Seethala RR and Stenman G: Update from the
4th Edition of the World Health Organization classification of head
and neck tumours: Tumors of the salivary gland. Head Neck Pathol.
11:55–67. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Luk PP, Selinger CI, Eviston TJ, Lum T, Yu
B, O'Toole SA, Clark JR and Gupta R: Mammary analogue secretory
carcinoma: An evaluation of its clinicopathological and genetic
characteristics. Pathology. 47:659–666. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Majewska H, Skalova A, Stodulski D,
Klimková A, Steiner P, Stankiewicz C and Biernat W: Mammary
analogue secretory carcinoma of salivary glands: A new entity
associated with ETV6 gene rearrangement. Virchows Arch.
466:245–254. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Boliere C, Murphy J, Qaisi M, Manosca F
and Fung H: Mammary analogue secretory carcinoma of the palate:
Case report and review of the literature. Case Rep Dent.
2019(7416302)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Stevens TM and Parekh V: Mammary analogue
secretory carcinoma. Arch Pathol Lab Med. 140:997–1001.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Shah AA, Wenig BM, LeGallo RD, Mills SE
and Stelow EB: Morphology in conjunction with immunohistochemistry
is sufficient for the diagnosis of mammary analogue secretory
carcinoma. Head Neck Pathol. 9:85–95. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Patel KR, Solomon IH, El-Mofty SK, Lewis
JS Jr and Chernock RD: Mammaglobin and S-100 immunoreactivity in
salivary gland carcinomas other than mammary analogue secretory
carcinoma. Hum Pathol. 44:2501–2508. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Khalele BA: Systematic review of mammary
analog secretory carcinoma of salivary glands at 7 years after
description. Head Neck. 39:1243–1248. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Skalova A: Mammary analogue secretory
carcinoma of salivary gland origin: An update and expanded
morphologic and immunohistochemical spectrum of recently described
entity. Head Neck Pathol 7. 1 (Suppl 1):S30–S36. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Luo Y, Kaz AM, Kanngurn S, Welsch P,
Morris SM, Wang J, Lutterbaugh JD, Markowitz SD and Grady WM: NTRK3
is a potential tumor suppressor gene commonly inactivated by
epigenetic mechanisms in colorectal cancer. PLoS Genet.
9(e1003552)2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Boon E, Valstar MH, van der Graaf WTA,
Bloemena E, Willems SM, Meeuwis CA, Slootweg PJ, Smit LA, Merkx
MAW, Takes RP, et al: Clinicopathological characteristics and
outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed
(mammary analogue) secretory carcinoma of salivary glands. Oral
Oncol. 82:29–33. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Skálová A, Vanecek T, Majewska H, Laco J,
Grossmann P, Simpson RH, Hauer L, Andrle P, Hosticka L, Branžovský
J and Michal M: Mammary analogue secretory carcinoma of salivary
glands with high-grade transformation: Report of 3 cases with the
ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and
CCND1 genes. Am J Surg Pathol. 38:23–33. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Brierley J, Gospodarowicz M and Wittekind
C: Head and Neck Tumours, Lip and Oral Cavity. In: TNM
Classification of Malignant Tumours. 8th edition. Wiley-Blackwell,
Toronto, pp17-54, 2017.
|
|
15
|
Chiosea SI, Griffith C, Assaad A and
Seethala RR: Clinicopathological characterization of mammary
analogue secretory carcinoma of salivary glands. Histopathology.
61:387–394. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Connor A, Perez-Ordonez B, Shago M,
Skálová A and Weinreb I: Mammary analog secretory carcinoma of
salivary gland origin with the ETV6 gene rearrangement by FISH:
Expanded morphologic and immunohistochemical spectrum of a recently
described entity. Am J Surg Pathol. 36:27–34. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sethi R, Kozin E, Remenschneider A, Meier
J, VanderLaan P, Faquin W, Deschler D and Frankenthaler R: Mammary
analogue secretory carcinoma: Update on a new diagnosis of salivary
gland malignancy. Laryngoscope. 124:188–195. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tokuzen N, Goda H and Nakashiro K: Locally
advanced mammary analogue secretory carcinoma of the parotid gland.
Int J Oral Maxillofac Surg. 48:865–868. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Slootweg PJ, Hordijk GJ, Schade Y, van Es
RJ and Koole R: Treatment failure and margin status in head and
neck cancer. A critical view on the potential value of molecular
pathology. Oral Oncol. 38:500–503. 2002.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Weiss MH, Harrison LB and Isaacs RS: Use
of decision analysis in planning a management strategy for the
stage N0 neck. Arch Otolaryngol Head Neck Surg. 120:699–702.
1994.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shah JP, Candela FC and Poddar AK: The
patterns of cervical lymph node metastases from squamous carcinoma
of the oral cavity. Cancer. 66:109–113. 1990.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bier J: Radical neck dissection versus
conservative neck dissection for squamous cell carcinoma of the
oral cavity. Recent Results Cancer Res. 134:57–62. 1994.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wolff KD, Al-Nawas B, Al-Sharif U, Beck J,
Bikowski K, Bissinger O, Böhme P, Bönte-Hieronymus I, Bootz F,
Bozzato A, et al: S3-Guidline regarding diagnosis and therapy of
oral cancer. Oncology Guideline Program. AWMF, 2012 (In German).
https://www.awmf.org/uploads/tx_szleitlinien/007-100OLl_S3-Diagnostik-Therapie-Mundhoehlenkarzinom_2021-03.pdf.
Accessed March 2021.
|
|
24
|
Fukuhara R, Shinya T, Fukuma S, Ogawa N,
Masaoka Y, Tanaka T, Marunaka H, Arioka T, Hiraki T, Kaji M and
Kanazawa S: The diagnostic capacity of pre-treatment
18F-FDG PET/CT for predicting the extranodular spread of
lymph node metastases in patients with oral squamous cell
carcinoma. Acta Med Okayama. 74:123–128. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Loo SW, Geropantas K, Beadsmoore C,
Montgomery PQ, Martin WM and Roques TW: Neck dissection can be
avoided after sequential chemoradiotherapy and negative
post-treatment positron emission tomography-computed tomography in
N2 head and neck squamous cell carcinoma. Clin Oncol (R Coll
Radiol). 23:512–517. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ferrell JK, Mace JC and Clayburgh D:
Contemporary treatment patterns and outcomes of salivary gland
carcinoma: A national cancer database review. Eur Arch
Otorhinolaryngol. 276:1135–1146. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Amatu A, Sartore-Bianchi A and Siena S:
NTRK gene fusions as novel targets of cancer therapy across
multiple tumour types. ESMO Open. 1(e000023)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ,
Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, et al: Safety and
antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK
inhibitor entrectinib: Combined results from two Phase I Trials
(ALKA-372-001 and STARTRK-1). Cancer Discov. 7:400–409.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Jiang T, Wang G, Liu Y, Feng L, Wang M,
Liu J, Chen Y and Ouyang L: Development of small-molecule
tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion
cancers. Acta Pharm Sin B. 11:355–372. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Drilon A, Laetsch TW, Kummar S, DuBois SG,
Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo
AS, et al: Efficacy of larotrectinib in TRK fusion-positive cancers
in adults and children. N Engl J Med. 378:731–739. 2018.PubMed/NCBI View Article : Google Scholar
|
